MGFA has partnered with Bionews to feature the Myasthenia Gravis News feed on our website, providing the community with research updates, disease management insights, and relevant news. All content is original and produced by Bionews’ editorial staff, and perspectives from patients and caregivers. Information is not meant to replace or provide medical advice.
Myasthenia Gravis News – The Web’s Daily Resource for Myasthenia Gravis News
- Neostigmine eyedrops may ease drooping of eyelids in MG patients
by Lila Levinson, PhD on May 20, 2026 at 2:45 pmAn eyedrop formulation of neostigmine, an acetylcholinesterase inhibitor (AChEI) whose oral formulation was once a mainstay treatment for myasthenia gravis (MG), may safely reduce drooping eyelids in people with the neuromuscular disease. That’s according to data from a small Phase 1 clinical trial (ACTRN12624000545561), which showed that one tested dose of the eyedrops, called topical The post Neostigmine eyedrops may ease drooping of eyelids in MG patients appeared first on Myasthenia Gravis News.
- Patients shouldn’t have to struggle so much because of healthcare costs
by Mark Harrington on May 20, 2026 at 2:00 pmFor those of us living with myasthenia gravis (MG), the burden isn’t confined to the body. It relentlessly finds its way into the wallets of those who live with it. Checkbooks, retirement accounts, pensions, and daily expenses are all affected and often determine whether one lives with dignity. In “David Copperfield,” Charles Dickens wrote, “Annual The post Patients shouldn’t have to struggle so much because of healthcare costs appeared first on Myasthenia Gravis News.
- Study has ‘wonderful news’ for MG patients considering pregnancy
by Marisa Wexler, MS on May 19, 2026 at 12:00 pmBeing pregnant does not increase the risk of hospitalizations for women with myasthenia gravis (MG), a study in Sweden found. Findings also indicate that the risk of MG-related hospitalization is not significantly increased after birth. However, for the minority of patients who are hospitalized during this period, these hospitalizations tend to be longer than hospitalizations The post Study has ‘wonderful news’ for MG patients considering pregnancy appeared first on Myasthenia Gravis News.
- Speak up about treatment side effects in MG
by Bionews Staff on May 19, 2026 at 11:00 amRetha De Wet shares why she wishes she had spoken up sooner about treatment side effects and reflects on the importance of self-advocacy while living with chronic illness. The post Speak up about treatment side effects in MG appeared first on Myasthenia Gravis News.
- Searching for answers with seronegative MG
by Bionews Staff on May 19, 2026 at 11:00 amJennifer Crow shares about pushing through multiple neurologists and barriers before receiving a diagnosis of seronegative MG. The post Searching for answers with seronegative MG appeared first on Myasthenia Gravis News.
** MGFA Disclaimer – Please read
Myasthenia Gravis Foundation of America (MGFA) and Bionews, Inc. (specifically Myasthenia Gravis News) have entered into a limited agreement that allows for the MGFA to post a link to Myasthenia Gravis News on the myasthenia.org website. Myasthenia Gravis News is a digital platform intended to provide the myasthenia gravis (MG) community with the most recent news and information on MG, as well as first-hand community perspectives from patient and caregiver columnists. All articles on Myasthenia Gravis News are original content produced by in-house writers and editors. Occasionally, Bionews seeks the opinion of outside experts for interviews and Q&As.
The publishing team at Myasthenia Gravis News is made up of science writers and editors, most of whom have PhDs in the life sciences; veteran journalists; and columnists who are members of the MG community. Together, they attempt to ensure that all content published on Myasthenia Gravis News is relevant, accurate, informative, relatable, and easy to understand.
Each piece of content is carefully selected and written by Bionews writers with the MG community in mind. Sources for news stories and resource pages include peer-reviewed studies, press releases, announcements, interviews, webinars, and conference sessions, among others. All articles go through a stringent fact-checking and editing procedure as part of Bionews’ process to ensure they are accurate, objective, comprehensive, and well-explained.
Columns are written by MG patients and caregivers who provide an intimate look at what it’s like to live with the disease. While columns are largely opinion and perspective pieces, each one still goes through a comprehensive editing and fact-checking process by Bionews editors to ensure clarity, accuracy, and fairness.
Myasthenia Gravis News’ site is strictly a news and information website about the disease. It DOES NOT provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The information provided is for educational purposes only and does not substitute for professional medical advice.
The content reflects the unique experiences of the authors and is not necessarily the opinion, views, or recommendations of the MGFA. Medical advisors and clinicians associated with or partnering with the MGFA do not peer review articles and information posted on the Myasthenia Gravis News platform or website. MGFA should not be liable for any information, opinions, articles, advice, guidance, or details posted on the Myasthenia Gravis News site. MGFA has posted this platform as a service to the MG community. Please consult with your doctor and healthcare professionals for specific recommendations and advice pertaining to your healthcare/treatment.